| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R44CA239940 | Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels | 000 | 3 | NIH | 4/10/2025 | $0 |
| | 2025 | 2022 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 001 | 2 | NIH | 4/25/2025 | $0 |
| | 2025 | 2022 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 000 | 2 | NIH | 4/16/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,701,459 ) |
| | 2024 | 2024 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 003 | 4 | NIH | 6/18/2024 | $1,528,057 |
| | 2024 | 2024 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 004 | 4 | NIH | 6/19/2024 | $98,701 |
| | 2024 | 2024 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 000 | 3 | NIH | 1/29/2024 | $37,149 |
| | 2024 | 2024 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 001 | 3 | NIH | 2/26/2024 | $37,552 |
| | 2024 | 2023 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 002 | 3 | NIH | 6/17/2024 | $0 |
| | 2024 | 2021 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43NS120410 | Optimization of a Gene Therapy for Chronic Pain in Human DRGs | 000 | 1 | NIH | 4/29/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,549,467 ) |
| | 2023 | 2023 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 002 | 3 | NIH | 9/12/2023 | $75,199 |
| | 2023 | 2023 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | SB1NS137964 | Advancing precision pain medicines to the clinic | 000 | 4 | NIH | 9/22/2023 | $400,000 |
| | 2023 | 2023 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 001 | 3 | NIH | 9/8/2023 | $1,074,268 |
| | 2023 | 2022 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 000 | 2 | NIH | 7/13/2023 | $0 |
| | 2023 | 2019 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43NS112088 | Repression of Sodium Channels via a Gene Therapy for Treatment of Chronic Neuropathic Pain | 000 | 1 | NIH | 8/22/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,147,533 ) |
| | 2022 | 2022 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R44CA239940 | Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels | 000 | 2 | NIH | 5/17/2022 | $44,695 |
| | 2022 | 2022 | NAVEGA THERAPEUTICS INC | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R44CA239940 | Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels | 002 | 3 | NIH | 8/19/2022 | $1,283,183 |
| | 2022 | 2022 | NAVEGA THERAPEUTICS INC | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R44CA239940 | Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels | 001 | 2 | NIH | 7/19/2022 | $89,391 |
| | 2022 | 2022 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 001 | 2 | NIH | 5/27/2022 | $730,264 |
| | 2022 | 2021 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 000 | 1 | NIH | 5/19/2022 | $0 |
| | 2022 | 2019 | NAVEGA THERAPEUTICS INC | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43CA239940 | Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels | 000 | 1 | NIH | 12/13/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,740,233 ) |
| | 2021 | 2021 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS122114 | Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | 000 | 1 | NIH | 6/1/2021 | $698,171 |
| | 2021 | 2021 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R44CA239940 | Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels | 000 | 2 | NIH | 9/10/2021 | $766,685 |
| | 2021 | 2021 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43NS120410 | Optimization of a Gene Therapy for Chronic Pain in Human DRGs | 000 | 1 | NIH | 9/17/2021 | $275,377 |
| | 2021 | 2019 | NAVEGA THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43NS112088 | Repression of Sodium Channels via a Gene Therapy for Treatment of Chronic Neuropathic Pain | 000 | 1 | NIH | 9/3/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $95,050 ) |
| | 2020 | 2020 | NAVEGA THERAPEUTICS, INC. | 2400 TORREY PINES RD | LA JOLLA | CA | 92037-3469 | SAN DIEGO | USA | R43NS112088 | Repression of Sodium Channels via a Gene Therapy for Treatment of Chronic Neuropathic Pain | 000 | 1 | NIH | 2/7/2020 | $95,050 |
|
| Issue Date FY: 2019 ( Subtotal = $817,290 ) |
| | 2019 | 2019 | NAVEGA THERAPEUTICS, INC. | 2400 TORREY PINES RD | LA JOLLA | CA | 92037-3469 | SAN DIEGO | USA | R43NS112088 | Repression of Sodium Channels via a Gene Therapy for Treatment of Chronic Neuropathic Pain | 000 | 1 | NIH | 9/16/2019 | $529,006 |
| | 2019 | 2019 | NAVEGA THERAPEUTICS, INC. | 2400 TORREY PINES RD | LA JOLLA | CA | 92037-3469 | SAN DIEGO | USA | R43CA239940 | Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels | 000 | 1 | NIH | 9/11/2019 | $288,284 |
|
|
